Lenalidomide and Blinatumomab in treating patients with Non-Hodgkin Lymphoma that has returned
Study of Immunotherapy (Lenalidomide and Blinatumomab) looking at side effects and best dose for treatment of lymphoma
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Grade 3b Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mediastinal Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Grade 1 Follicular Lymphoma Refractory Grade 2 Follicular Lymphoma Refractory Grade 3 Follicular Lymphoma Refractory Grade 3a Follicular Lymphoma Refractory Mantle Cell Lymphoma Refractory Marginal Zone Lymphoma Refractory Mediastinal Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Small Lymphocytic Lymphoma Burkitt Lymphoma Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Hodgkin Disease Lymphoma, Mantle-Cell Lymphoma, B-Cell, Marginal Zone Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Large B-Cell, Diffuse Antineoplastic Agents, Immunological Lenalidomide Blinatumomab Antibodies Immunoglobulins Antibodies, Monoclonal Muromonab-CD3 Antibodies, Bispecific
Lead Scientist at UC Davis
- Joseph M. Tuscano
Professor, Hematology and Oncology. Authored (or co-authored) 94 research publications.